Riskpilot← Back to searchSign inGet full accessVitasalus AB
ABActiveOrg 5569068363Kaserngården 4General medical practice activities · NACE 8621Est. 20121 employees
Revenue 2025
SEK 1,3M
+810% vs 2024
EBITDA margin
1.8%
-38% vs 2024
Equity ratio
4.4%
Financial strength
Net profit 2025
SEK 4K
-82% vs 2024
| Revenue | SEK 1,3M | +810% |
| EBITDA | SEK 23K | -38% |
| Net profit | SEK 4K | -82% |
| Total assets | SEK 1,2M | +572% |
| Equity | SEK 52K | +8% |
| Employees | 1 | — |
Legal name
Vitasalus AB
Org number
5569068363
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
15 oktober 2012
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget skall bedriva läkarbemanning och vårdtjänster. Bolaget skall även vara verksamt inom hälsotester, hälsoanalyser, behandlingar och konsultationer inom hälso- och sjukvård. Bolaget ska även vara verksamt inom tester och analyser av blod samt därmed förenlig verksamhet.
Address
Kaserngården 4
Email
info@vitasalus.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 10 | 0 | 0 | 138 | 1 258 |
| Staff expenses | — | — | — | −2 | −220 |
| EBITDA | 4 | 3 | −0 | 37 | 23 |
| Depreciation & amort. | −0 | — | — | −9 | −16 |
| EBIT | 4 | 3 | −0 | 28 | 7 |
| Net financials | — | −6 | 0 | 0 | 0 |
| Profit before tax | 4 | −4 | −0 | 28 | 7 |
| Tax | −0 | — | — | −6 | −3 |
| Net profit | 4 | −4 | −0 | 22 | 4 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 142 | 35 | 34 | 176 | 1 180 |
| Equity | 30 | 26 | 26 | 48 | 52 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 112 | 9 | 8 | 128 | 1 128 |
| Total debt | 112 | 9 | 8 | 128 | 1 128 |
EBITDA margin
1.8%
This company
15.8%
Market median
-89% vs market
20212025
Equity ratio
4.4%
This company
38.2%
Market median
-88% vs market
20212025
Return on equity
7.6%
This company
18.4%
Market median
-59% vs market
20212025
Net profit margin
0.3%
This company
8.1%
Market median
-96% vs market
20212025
Asset turnover
1.07×
This company
1.12×
Market median
+4% vs market
20212025
Debt / equity
21.70×
This company
0.62×
Market median
-3400% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MC Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (2) | ||
SA Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
OP Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2026 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Triventa AB
Vitasalus AB Board members of Vitasalus AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stig Anders Emanuel Lindstedt | Chief Executive Officer | 0 companies |
| Ola Per Svensson | Chief Executive Officer | 0 companies |
| Maria Camilla Victoria Janericsdotter Dofs | Chief Executive Officer | 0 companies |
| Claes Göran Patrik Dofs | Board of Directors | 0 companies |
| Joakim Anders Christian Dofs | Chairman | 0 companies |